Get the Stockscreener App
0.236
4.80%
-0.0119
Cyclacel Pharmaceuticals Inc stock is traded at $0.236, with a volume of 2.59M.
It is down -4.80% in the last 24 hours and down -85.87% over the past month.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$0.2479
Open:
$0.2479
24h Volume:
2.59M
Relative Volume:
2.12
Market Cap:
$6.62M
Revenue:
$74,000
Net Income/Loss:
$-13.43M
P/E Ratio:
-0.0251
EPS:
-9.4
Net Cash Flow:
$-10.54M
1W Performance:
-32.53%
1M Performance:
-85.87%
6M Performance:
-96.79%
1Y Performance:
-99.10%
1-Day Range:
$0.215
$0.25
1-Week Range:
$0.215
$0.353
52-Week Range:
$0.215
$39.84
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Name
Cyclacel Pharmaceuticals Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Compare CYCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.236 | 6.62M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Apr-27-20 | Resumed | ROTH Capital | Buy |
| Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-15 | Initiated | H.C. Wainwright | Buy |
| Feb-04-10 | Initiated | Roth Capital | Buy |
| Oct-28-09 | Initiated | Merriman | Buy |
| Aug-12-08 | Initiated | Piper Jaffray | Buy |
| Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-12-08 | Reiterated | Collins Stewart | Buy |
| Mar-12-08 | Reiterated | Needham & Co | Buy |
| Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-04-07 | Reiterated | Needham & Co | Buy |
| Apr-23-07 | Initiated | Lazard Capital | Buy |
| Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Cyclacel Pharmaceuticals Inc Stock (CYCC) Latest News
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Listing Rule - marketscreener.com
Cyclacel Pharmaceuticals Declares Quarterly Cash Dividend - TipRanks
Cyclacel Pharmaceuticals (CYCC) Regains Nasdaq Compliance | CYCC Stock News - GuruFocus
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM - GuruFocus
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Cyclacel Dodges Delisting Risk: Stock Stabilizes Above $1, Secures Crucial Nasdaq Compliance - Stock Titan
Comparing Cyclacel Pharmaceuticals (NASDAQ:CYCC) and Biodexa Pharmaceuticals (NASDAQ:BDRX) - Defense World
Cyclacel stock plunges to 52-week low of $1.95 amid market challenges - Investing.com Australia
(CYCCP) Proactive Strategies - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - The Manila Times
Cyclacel Pharmaceuticals Reports Q1 2025 Financial Results and Strategic Focus Shifts to Plogosertib Development - Nasdaq
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Fitters Clarifies Details Of Business Unit Disposal To Cyclacel - BusinessToday Malaysia
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Monday - Defense World
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com - Defense World
Trend Tracker for (CYCCP) - news.stocktradersdaily.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Shares Scheduled to Reverse Split on Monday, May 12th - Defense World
Cyclacel Pharmaceuticals Announces Reverse Stock Split - TipRanks
Cyclacel Pharmaceuticals to implement 1-for-16 reverse stock split; shares fall - MSN
Cyclacel Pharmaceuticals (CYCC) Plans 1-for-16 Reverse Stock Split | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Announces Stock Split - marketscreener.com
Cyclacel Pharmaceuticals Announces 1-for-16 Reverse Stock Split Effective May 12, 2025 - Nasdaq
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT - The Manila Times
Cyclacel Pharmaceuticals enters exchange agreement with Fitters - TipRanks
Cyclacel Pharmaceuticals (CYCC) Plans Strategic Acquisition and Rebranding | CYCC Stock News - GuruFocus
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCH - GuruFocus
Fitters swaps fire safety arm for 19.99% stake in Nasdaq biotech firm - The Malaysian Reserve
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE - The Manila Times
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE - GlobeNewswire
Cyclacel's Major Transformation: 80% Stake in Malaysian Fire Safety Leader Signals Strategic Pivot - Stock Titan
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Stocks of Cyclacel Pharmaceuticals Inc (CYCC) are poised to climb above their peers - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Examining Cyclacel Pharmaceuticals Inc (CYCC) more closely is necessary - uspostnews.com
The Psychology of Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: Understanding Market Sentiment - investchronicle.com
Cyclacel Pharmaceuticals (CYCC) Announces Quarterly Dividend - GuruFocus
Cyclacel Pharmaceuticals expands share authorization By Investing.com - Investing.com India
Cyclacel Pharmaceuticals expands share authorization - Investing.com
Major Shareholders Set to Sell Stocks; Company (TICKER) to Reap No Proceeds | CYCC Stock News - GuruFocus
Cyclacel Pharmaceuticals Inc Inc. (CYCC) Price Performance: A Technical Analysis Perspective - investchronicle.com
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Could Actually Go To 1 In 12 Months - Marketing Sentinel
Was Cyclacel Pharmaceuticals Inc (CYCC)’s session last reading good? - uspostnews.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Trading (CYCCP) With Integrated Risk Controls - news.stocktradersdaily.com
Cyclacel Pharmaceuticals announces preferred stock dividend By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Inc Stock (CYCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):